

Table S1. The targeting sequences and shRNA sequences used in construction

Gene	Target sequence	No.	shRNA sequence
ALDH9A1	TTGGTTATACCAGAAGAGAAC	Pbr-17162a	ccggTTGGTTATACCAGAAGAGAACctcgagGTTCTCTTCTGGTATAACCAAttttg
ALDH9A1		Pbr-17162b	aattcaaaaaTTGGTTATACCAGAAGAGAACctcgagGTTCTCTTCTGGTATAACCAA
ALDH9A1	TCCCAAATTAAGGATGGATA	Pbr-17163a	ccggTCCCAAATTAAGGATGGATActcgagTATCCATCCTTTAATTTGGGAttttg
ALDH9A1		Pbr-17163b	aattcaaaaaTCCCAAATTAAGGATGGATActcgagTATCCATCCTTTAATTTGGGA
ALDH9A1	ACCTTGGAACCTTGAGGCAAA	Pbr-17164a	ccggACCTTGGAACCTTGAGGCAAActcgagTTTGCCTCCAAGTTCCAAGGTttttg
ALDH9A1		Pbr-17164b	aattcaaaaaACCTTGGAACCTTGAGGCAAActcgagTTTGCCTCCAAGTTCCAAGGT
CDKL3	GAGGAGATATCTCAGAACCAA	Pbr-10064a	ccggGAGGAGATATCTCAGAACCAAactcgagTTGGTTCTGAGATATCTCCTCttttg
CDKL3		Pbr-10064b	aattcaaaaaGAGGAGATATCTCAGAACCAAactcgagTTGGTTCTGAGATATCTCCTC
CDKL3	ACTAACTGTAATGGCTTGAAA	Pbr-00158a	ccggACTAACTGTAATGGCTTGAAAactcgagTTTCAAGCCATTACAGTTAGTttttg
CDKL3		Pbr-00158b	aattcaaaaaACTAACTGTAATGGCTTGAAAactcgagTTTCAAGCCATTACAGTTAGT
CDKL3	CACACAGTATTAGATGAGTTA	Pbr-00159a	ccggCACACAGTATTAGATGAGTTActcgagTAACTCATCTAATACTGTGTGttttg
CDKL3		Pbr-00159b	aattcaaaaaCACACAGTATTAGATGAGTTActcgagTAACTCATCTAATACTGTGTG
CSNK1D	ACGGACATTGCTGCAGGAGAA	Pbr-16375a	ccggACGGACATTGCTGCAGGAGAAactcgagTTCTCCTGCAGCAATGTCCGTttttg
CSNK1D		Pbr-16375b	aattcaaaaaACGGACATTGCTGCAGGAGAAactcgagTTCTCCTGCAGCAATGTCCGT
CSNK1D	GACAGAAATACGAAAGGATTA	Pbr-16376a	ccggGACAGAAATACGAAAGGATTAactcgagTAATCCTTTCGTATTTCTGTCTttttg
CSNK1D		Pbr-16376b	aattcaaaaaGACAGAAATACGAAAGGATTAactcgagTAATCCTTTCGTATTTCTGTCT
CSNK1D	CGGCATGGAGAGAGAGCGGAA	Pbr-16377a	ccggCGGCATGGAGAGAGAGCGGAAactcgagTTCCGCTCTCTCCATGCCGttttg

CSNK1D		Pbr-16377b	aattcaaaaaCGGCATGGAGAGAGAGCGGAActcgagTTCCGCTCTCTCTCCATGCCG
ERCC8	ACTAGAGGACCCAAAGTACAA	Pbr-13855a	ccggACTAGAGGACCCAAAGTACAActcgagTTGTACTTTGGGTCCTCTAGTtttttg
ERCC8		Pbr-13855b	aattcaaaaaACTAGAGGACCCAAAGTACAActcgagTTGTACTTTGGGTCCTCTAGT
ERCC8	GTATGGGATACAAATACATTA	Pbr-13856a	ccggGTATGGGATACAAATACATTActcgagTAATGTATTTGTATCCCATACtttttg
ERCC8		Pbr-13856b	aattcaaaaaGTATGGGATACAAATACATTActcgagTAATGTATTTGTATCCCATAC
ERCC8	AGTCTGGATCCTGTTCTCACA	Pbr-13857a	ccggAGTCTGGATCCTGTTCTCACActcgagTGTGAGAACAGGATCCAGACTtttttg
ERCC8		Pbr-13857b	aattcaaaaaAGTCTGGATCCTGTTCTCACActcgagTGTGAGAACAGGATCCAGACT
EZR	GGCCAAAGAAGCCCAGGATGA	Pbr-12106a	ccggGGCCAAAGAAGCCCAGGATGActcgagTCATCCTGGGCTTCTTTGGCCtttttg
EZR		Pbr-12106b	aattcaaaaaGGCCAAAGAAGCCCAGGATGActcgagTCATCCTGGGCTTCTTTGGCC
EZR	GAGAGAAACCGTGGAGAGAGA	Pbr-12107a	ccggGAGAGAAACCGTGGAGAGAGActcgagTCTCTCTCCACGGTTTCTCTCtttttg
EZR		Pbr-12107b	aattcaaaaaGAGAGAAACCGTGGAGAGAGActcgagTCTCTCTCCACGGTTTCTCTC
EZR	CGTGTACGAGCCGGTGAGCTA	Pbr-12108a	ccggCGTGTACGAGCCGGTGAGCTActcgagTAGCTCACCGGCTCGTACACGtttttg
EZR		Pbr-12108b	aattcaaaaaCGTGTACGAGCCGGTGAGCTActcgagTAGCTCACCGGCTCGTACACG
HADHA	ATGCTGACTGGTAGAAGCATT	Pbr-17306a	ccggATGCTGACTGGTAGAAGCATTctcgagAATGCTTCTACCAGTCAGCATtttttg
HADHA		Pbr-17306b	aattcaaaaaATGCTGACTGGTAGAAGCATTctcgagAATGCTTCTACCAGTCAGCAT
HADHA	TGCCAAAGGACTAGCTGATAA	Pbr-17307a	ccggTGCCAAAGGACTAGCTGATAActcgagTTATCAGCTAGTCCTTTGGCAtttttg
HADHA		Pbr-17307b	aattcaaaaaTGCCAAAGGACTAGCTGATAActcgagTTATCAGCTAGTCCTTTGGCA
HADHA	GAGGTTGCCATTTTCATGCCAA	Pbr-17308a	ccggGAGGTTGCCATTTTCATGCCAActcgagTTGGCATGAAATGGCAACCTCtttttg
HADHA		Pbr-17308b	aattcaaaaaGAGGTTGCCATTTTCATGCCAActcgagTTGGCATGAAATGGCAACCTC

SDHC	TTCTTACTGTGTTGTCCTCTA	Pbr-11628a	ccggTTCTTACTGTGTTGTCCTCTActcgagTAGAGGACAACACAGTAAGAAtttttg
SDHC		Pbr-11628b	aattcaaaaaTTCTTACTGTGTTGTCCTCTActcgagTAGAGGACAACACAGTAAGAA
SDHC	TTGGTCTCTTCCCATGGCGAT	Pbr-11629a	ccggTTGGTCTCTTCCCATGGCGATctcgagATCGCCATGGGAAGAGACCAAtttttg
SDHC		Pbr-11629b	aattcaaaaaTTGGTCTCTTCCCATGGCGATctcgagATCGCCATGGGAAGAGACCAA
SDHC	CCTGAAGATTCCCCAGCTATA	Pbr-11630a	ccggCCTGAAGATTCCCCAGCTATAActcgagTATAGCTGGGGAATCTTCAGGtttttg
SDHC		Pbr-11630b	aattcaaaaaCCTGAAGATTCCCCAGCTATAActcgagTATAGCTGGGGAATCTTCAGG
SPRTN	AATCAAGGAACCAGAGAATTA	Pbr-13786a	ccggAATCAAGGAACCAGAGAATTAActcgagTAATTCTCTGGTTCCTTGATTtttttg
SPRTN		Pbr-13786b	aattcaaaaaAATCAAGGAACCAGAGAATTAActcgagTAATTCTCTGGTTCCTTGATT
SPRTN	CCAGTATTGGCCGCAGAGAAT	Pbr-13787a	ccggCCAGTATTGGCCGCAGAGAATctcgagATTCTCTGCGGCAATACTGGtttttg
SPRTN		Pbr-13787b	aattcaaaaaCCAGTATTGGCCGCAGAGAATctcgagATTCTCTGCGGCAATACTGG
SPRTN	CCGTATTACGGCTATGTCAAA	Pbr-13788a	ccggCCGTATTACGGCTATGTCAAAActcgagTTTGACATAGCCGTAATACGGtttttg
SPRTN		Pbr-13788b	aattcaaaaaCCGTATTACGGCTATGTCAAAActcgagTTTGACATAGCCGTAATACGG
TRPS1	ATGCTGCAGAACTAAATCATA	Pbr-11698a	ccggATGCTGCAGAACTAAATCATAActcgagTATGATTTAGTTCTGCAGCATtttttg
TRPS1		Pbr-11698b	aattcaaaaaATGCTGCAGAACTAAATCATAActcgagTATGATTTAGTTCTGCAGCAT
TRPS1	CACCAAGTATTTCCGCTGTAA	Pbr-11699a	ccggCACCAAGTATTTCCGCTGTAAActcgagTTACAGCGGAAATACTTGGTGtttttg
TRPS1		Pbr-11699b	aattcaaaaaCACCAAGTATTTCCGCTGTAAActcgagTTACAGCGGAAATACTTGGTG
TRPS1	GTGCCAATTGCCTGACCACAA	Pbr-11700a	ccggGTGCCAATTGCCTGACCACAAActcgagTTGTGGTCAGGCAATTGGCACtttttg
TRPS1		Pbr-11700b	aattcaaaaaGTGCCAATTGCCTGACCACAAActcgagTTGTGGTCAGGCAATTGGCAC
ZMPSTE24	GAGGGAAAGCTTAAAGAAGAA	Pbr-16714a	ccggGAGGGAAAGCTTAAAGAAGAAActcgagTTCTTCTTAAAGCTTTCCCTCtttttg

ZMPSTE24		Pbr-16714b	aattcaaaaaGAGGGAAAGCTTAAAGAAGAAActcgagTTCTTCTTTAAGCTTTCCCTC
ZMPSTE24	AGCGGCAGAGAAGGATATATA	Pbr-16715a	ccggAGCGGCAGAGAAGGATATATAActcgagTATATATCCTTCTCTGCCGCTttttg
ZMPSTE24		Pbr-16715b	aattcaaaaaAGCGGCAGAGAAGGATATATAActcgagTATATATCCTTCTCTGCCGCT
ZMPSTE24	TAACAAAGATAACTTGGGATT	Pbr-16716a	ccggTAACAAAGATAACTTGGGATTctcgagAATCCCAAGTTATCTTTGTTAttttg
ZMPSTE24		Pbr-16716b	aattcaaaaaTAACAAAGATAACTTGGGATTctcgagAATCCCAAGTTATCTTTGTTA
RRM2	CGGAGGAGAGAGTAAGAGAAA	Pbr48744a	CcggCGGAGGAGAGAGTAAGAGAAAActcgagTTTCTCTTACTCTCTCCTCCGttttg
RRM2		Pbr48744b	aattcaaaaaCGGAGGAGAGAGTAAGAGAAAActcgagTTTCTCTTACTCTCTCCTCCG
RRM2	GCTCAAGAAACGAGGACTGAT	Pbr48745a	CcggGCTCAAGAAACGAGGACTGATctcgagATCAGTCCTCGTTTCTTGAGCttttg
RRM2		Pbr48745b	aattcaaaaaGCTCAAGAAACGAGGACTGATctcgagATCAGTCCTCGTTTCTTGAGC
RRM2	GCAGATGTATAAGAAGGCAGA	Pbr48746a	CcggGCAGATGTATAAGAAGGCAGActcgagTCTGCCTTCTTATACATCTGCttttg
RRM2		Pbr48746b	aattcaaaaaGCAGATGTATAAGAAGGCAGActcgagTCTGCCTTCTTATACATCTGC

Table S2. Antibodies used in Western blot analysis.

Primary antibodyies	Dilution	Company
CDKL3	1:1000	Bioss
GAPDH	1:3000	Bioworld
N-cadherin	1:5000	Abcam
Vimentin	1:1000	Abcam
Snail	1:1000	Abcam
ERK	1:1000	Abcam
p-ERK	1:1000	Abcam
JNK	1:1000	Abcam
p-JNK	1:1000	Abcam
P38	1:1000	Abcam
p-P38	1:1000	Abcam
MEK	1:3000	CST
p-MEK	1:500	Bioss
EGFR	1:1000	Abcam
RRM2	1:1000	Abcam
PPM1A	1:1000	Abcam
CD133	1:1000	abcam
MELK	1:1000	abcam
SOX2	1:1000	abcam
TLR4	1:1000	SANTA CRUZ
NF- κ B	1:1000	CST
c-Myc	1:1000	CST
Secondary antibody		
HRP Goat Anti-Rabbit IgG	1:3000	Beyotime
HRP Goat Anti-Mouse IgG	1:3000	Beyotime

Table S3. Clinicopathological characteristics of 149 glioblastoma patients recruited in the detection of RRM2.

Characteristics	Patients (n = 149)	RRM2 Expression	
		Low	High
Gender			
Male	96 (64.4%)	46	50
Female	53 (35.6%)	28	25
Tumor recurrence			
No	68 (45.6%)	55	13
Yes	81 (54.4%)	19	62
Grade			
I	17 (11.4%)	15	2
II	70 (47.0%)	51	19
III	44 (29.5%)	8	36
IV	18 (12.1%)	0	18